Company Overview
Snapshot
Founded in January 2020 by David Risin and Dr. Ayelet Ben Barak, LIBI-Diagnostics operates with 1–10 employees. The company has secured funding across one round from one investor, Headstart, for its work in cancer diagnostics.
Business overview
LIBI-Diagnostics is a Health Tech & Life Sciences startup focused on the early detection of cancer through gene-biomarker tests. The company utilizes next-generation bio-liquid tests and state-of-the-art Next-Generation Sequencing (NGS) technology to customize tests for each patient. By detecting alterations of Aurora Kinase A in blood or urine samples, LIBI-Diagnostics aims to identify recurrent cancerous development at an early stage, serving the healthcare and patient markets with non-invasive diagnostic solutions.
Log in to access full profile ›Company Intelligence Q&A
- What is LIBI-Diagnostics' primary focus?
- LIBI-Diagnostics focuses on the early detection of cancer through gene-biomarker tests, utilizing next-generation bio-liquid tests and Next-Generation Sequencing (NGS) technology.
- When was LIBI-Diagnostics founded?
- LIBI-Diagnostics was founded in January 2020.
- Who are the founders of LIBI-Diagnostics?
- The company was founded by David Risin and Dr. Ayelet Ben Barak.
- What technology does LIBI-Diagnostics use for its diagnostic tests?
- LIBI-Diagnostics uses state-of-the-art Next-Generation Sequencing (NGS) technology to detect alterations of Aurora Kinase A in patient samples.